Sialyllactose Alleviates Streptozotocin-Induced Diabetes through Anti-Inflammatory and Metabolic Modulation.

ABSTRACT: Diabetes mellitus (DM) is a disorder characterized by hyperglycemia, inflammation, and impaired metabolic activities. This study investigated the effects of sialyllactose (SL), a subgroup of human milk oligosaccharides, on streptozotocin (STZ)-induced type 1 diabetes mellitus (T1DM) in vivo. Male ICR mice were preadministered SL followed by a single intraperitoneal injection of STZ to establish the T1DM model. The evaluation was conducted through biochemical analyses, glucose and insulin tolerance tests, histological assessments, qRT-PCR, and western blotting. We found that SL pretreatment improved body weight, glucose tolerance, and fasting blood glucose levels in mice. SL mitigated STZ-induced organ injury, as evidenced by histological analysis and serum markers of liver, pancreas

SUBMITTER: Tran-Duc PN 

PROVIDER: S-EPMC12580643 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature